The findings from the various assessments are then combined to give an individualised risk of the pregnancy being affected by Down’s Syndrome. Maternal blood is also taken to measure levels of Beta Human Chorionic Gonadotrophin (the pregnancy hormone) and Pregnancy Associated Plasma Protein A (a protein produced by the developing placenta). The ultrasound markers that are used for this test are measurement of the nuchal translucency, presence or absence of the nasal bone and tricuspid regurgitation, assessment of flow in the ductus venosus and detailed examination of the baby’s anatomy. The Combined Test is a screening test that measures various ultrasound and biochemical (substances in the mothers blood) markers to give an individualised risk of a pregnancy being affected with Down’s Syndrome. The chance of having a baby with Down’s Syndrome increases as the mother gets older but there is a risk for women of all ages. It is a chromosomal abnormality caused by the presence of an extra chromosome 21. This is a detailed ultrasound scan of the baby and an opportunity to screen for chromosomal abnormalities, mainly Down’s syndrome, Edward’s syndrome and Patau’s syndrome.ĭown’s Syndrome is the most common cause of learning disability. This ultrasound scan aims to confirm the presence of a heartbeat, determine the number of babies present and the expected date of delivery (dating). Nuchal translucency and Nasal Bone Assessment
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |